Packages (Simulation)
Reagent Preparation
Image (I)
-
Results demonstration
Image (II)
-
Typical Standard Curve
Quality Guarantee
Instruction Manual
Certificate
Maybe you can also pay attention to our smart microplate reader
High Sensitive ELISA Kit for Leucine Rich Alpha-2-Glycoprotein 1 (LRG1)
- Product No.HEB934Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample TypeSerum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3h
- Detection Range0.312-20ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.134ng/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
- FOB
US$ 512
US$ 732
US$ 3294
US$ 6222
US$ 51240
For more details, please contact local distributors!
Specificity
This assay has high sensitivity and excellent specificity for detection of High Sensitive Leucine Rich Alpha-2-Glycoprotein 1 (LRG1).
No significant cross-reactivity or interference between High Sensitive Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant High Sensitive Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) and the recovery rates were calculated by comparing the measured value to the expected amount of High Sensitive Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 97-105 | 101 |
| EDTA plasma(n=5) | 83-97 | 90 |
| heparin plasma(n=5) | 86-96 | 92 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level High Sensitive Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level High Sensitive Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of High Sensitive Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 79-101% | 80-101% | 91-101% | 97-105% |
| EDTA plasma(n=5) | 78-98% | 86-96% | 80-94% | 93-101% |
| heparin plasma(n=5) | 90-97% | 96-105% | 89-96% | 96-103% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
| Standard | 2 | Standard Diluent | 1×20mL |
| Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
| Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
| TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
| Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.
GIVEAWAYS
INCREMENT SERVICES
| Magazine | Citations |
| Clin Exp Nephrol | Differentially expressed urinary biomarkers in children with idiopathic nephrotic syndrome PubMed: 26351173 |
| Journal of Proteome Research | Targeted proteomics predict a sustained complete-response after transarterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma: a prospective cohort study pubmed:28112944 |
| OncoTargets and Therapy | leucine-rich alpha-2-glycoprotein-1 is up-regulated in colorectal cancer and is a tumor promoter Pubmed:29785123 |
| PROTEOMICS – Clinical Applications | Screening and Identification of Pregnancy Zone Protein (PZP) and Leucine‐Rich Alpha‐2‐Glycoprotein (LRG) as Potential Serum Biomarkers for Early‐onset … Pubmed: 30411527 |
| Cancer Management and Research | iTRAQ-based quantitative protein expression profiling of biomarkers in childhood B-cell and T-cell acute lymphoblastic leukemia Pubmed: 31440093 |
| J Clin Med | A Three-Protein Panel to Support the Diagnosis of Sepsis in Children Pubmed:35329889 |